XOMA Royalty Corporation

NasdaqGM:XOMA Voorraadrapport

Marktkapitalisatie: US$355.6m

XOMA Royalty Toekomstige groei

Future criteriumcontroles 5/6

XOMA Royalty is forecast to grow earnings and revenue by 74.3% and 32.6% per annum respectively while EPS is expected to grow by 76.9% per annum.

Belangrijke informatie

74.3%

Groei van de winst

76.9%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei32.6%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt14 Aug 2024

Recente toekomstige groei-updates

Recent updates

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Aug 14
News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

Aug 02
Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 29

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Apr 03
Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Sep 01
Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Aug 11
Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Aug 04

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

May 08
Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

Xoma Gets The Spotlight

Sep 02

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Aug 20
Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

May 13
We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

May 11
Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

XOMA EPS misses by $0.55, misses on revenue

May 06

XOMA gets milestone payment from Janssen Biotech

May 03

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Mar 17
XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Mar 16
Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Mar 09
Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Feb 02
Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

XOMA: A Royalty Aggregator To Watch

Jan 04

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Dec 29
XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

XOMA prices $22M offering of series A cumulative perpetual preferred stock

Dec 11

Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Dec 01
Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Winst- en omzetgroeiprognoses

NasdaqGM:XOMA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026462N/AN/A3
12/31/202534-8N/AN/A3
12/31/2024264N/AN/A3
6/30/202415-25-8-8N/A
3/31/20246-42-13-18N/A
12/31/20235-46-18-18N/A
9/30/20234-32-18-18N/A
6/30/20234-31-20-20N/A
3/31/20233-30-14-17N/A
12/31/20226-23-13-13N/A
9/30/202240104222N/A
6/30/202241103622N/A
3/31/202241123623N/A
12/31/20213882323N/A
9/30/2021301-1110N/A
6/30/2021296-310N/A
3/31/2021296-211N/A
12/31/20202991010N/A
9/30/20202-13-12-12N/A
6/30/202011-9-18-5N/A
3/31/202011-10-25-6N/A
12/31/201918-2-200N/A
9/30/201920-2-181N/A
6/30/201912-8-27-5N/A
3/31/201913-6-21-6N/A
12/31/20185-13-28-13N/A
9/30/20189-11-30-15N/A
6/30/20184491818N/A
3/31/20185318N/A13N/A
12/31/2017536N/A3N/A
9/30/201748-11N/A15N/A
6/30/201712-39N/A-28N/A
3/31/20172-61N/A-32N/A
12/31/20166-54N/A-34N/A
9/30/201653-11N/A-12N/A
6/30/2016551N/A-19N/A
3/31/201657-7N/A-23N/A
12/31/201555-21N/A-31N/A
9/30/201512-53N/A-77N/A
6/30/201515-67N/A-74N/A
3/31/201518-55N/A-74N/A
12/31/201419-38N/A-78N/A
9/30/201427-83N/A-68N/A
6/30/201428-99N/A-65N/A
3/31/201429-104N/A-60N/A
12/31/201335-124N/A-46N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: XOMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Winst versus markt: XOMA is forecast to become profitable over the next 3 years, which is considered above average market growth.

Hoge groeiwinsten: XOMA is expected to become profitable in the next 3 years.

Omzet versus markt: XOMA's revenue (32.6% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: XOMA's revenue (32.6% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven